{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:56:13Z","timestamp":1791849373587,"version":"4.3.4"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.sxmr.2017.02.004","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T12:15:51Z","timestamp":1491653751000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["The Safety and Efficacy of Growth Hormone Secretagogues"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-9626","authenticated-orcid":false,"given":"John T.","family":"Sigalos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Pastuszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2017.02.004_bib1","series-title":"UpToDate","article-title":"Physiology of growth hormone","author":"Melmed","year":"2008"},{"key":"10.1016\/j.sxmr.2017.02.004_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrendo.2010.123","article-title":"The growth hormone receptor: mechanism of activation and clinical implications","volume":"6","author":"Brooks","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1210\/jcem.83.2.4594","article-title":"Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee","volume":"83","author":"Carroll","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2265.1992.tb02287.x","article-title":"The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition","volume":"37","author":"Binnerts","year":"1992","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1530\/eje.0.1330445","article-title":"Resting metabolic rate, body composition and related hormonal parameters in growth hormone-deficient adults before and after growth hormone replacement therapy","volume":"133","author":"Snel","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2265.1994.tb02451.x","article-title":"Energy expenditure and body composition in growth hormone deficient adults on\u00a0exogenous growth hormone","volume":"40","author":"Chong","year":"1994","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1530\/acta.0.1250449","article-title":"Long-term growth hormone treatment in growth hormone deficient adults","volume":"125","author":"Jorgensen","year":"1991","journal-title":"Acta Endocinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2265.1992.tb02901.x","article-title":"Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study","volume":"36","author":"Whitehead","year":"1992","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1152\/jappl.1991.70.2.688","article-title":"Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength","volume":"70","author":"Cuneo","year":"1991","journal-title":"J\u00a0Appl Physiol (1985)"},{"key":"10.1016\/j.sxmr.2017.02.004_bib10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1152\/jappl.1991.70.2.695","article-title":"Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance","volume":"70","author":"Cuneo","year":"1991","journal-title":"J\u00a0Appl Physiol (1985)"},{"key":"10.1016\/j.sxmr.2017.02.004_bib11","first-page":"552","article-title":"Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood","volume":"80","author":"Nass","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib12","first-page":"41","article-title":"Quadriceps strength before and after growth hormone replacement in hypopituitary adults: relationship to changes in lean body mass and IGF-I","volume":"1","author":"Rutherford","year":"1994","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib13","unstructured":"Blue Cross Blue Shield. Drug info. Available at: https:\/\/www.anthem.com\/provider\/noapplication\/f0\/s0\/t0\/pw_e236012.pdf?na=pharminfo. Accessed March 27, 2017."},{"key":"10.1016\/j.sxmr.2017.02.004_bib14","unstructured":"Food and Drug Administration. FDA Drug Safety Podcast for\u00a0Healthcare Professionals: Ongoing safety review of recombinant human growth hormone (somatropin) and possible increased risk of death. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafetyDrugSafetyPodcasts\/ucm238349.htm. Acessed March 27, 2017."},{"key":"10.1016\/j.sxmr.2017.02.004_bib15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1468-1293.2010.00906.x","article-title":"Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials","volume":"12","author":"Sivakumar","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.sxmr.2017.02.004_bib16","doi-asserted-by":"crossref","first-page":"E494","DOI":"10.1152\/ajpendo.00013.2005","article-title":"Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting","volume":"289","author":"Esposito","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1468-1293.2006.00380.x","article-title":"Counteracting muscle wasting in HIV-infected individuals","volume":"7","author":"Dudgeon","year":"2006","journal-title":"HIV Med"},{"key":"10.1016\/j.sxmr.2017.02.004_bib18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1210\/jc.2011-1995","article-title":"Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study","volume":"97","author":"Carel","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.med.54.101601.152147","article-title":"Growth hormone therapy in adults","volume":"54","author":"Cummings","year":"2003","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.sxmr.2017.02.004_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/cen.12848","article-title":"Growth hormone replacement does not increase mortality in patients with childhood-onset growth hormone deficiency","volume":"83","author":"Berglund","year":"2015","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.279.5350.563","article-title":"Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study","volume":"279","author":"Chan","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.sxmr.2017.02.004_bib22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1210\/endo-106-3-663","article-title":"Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in\u00a0vitro","volume":"106","author":"Bowers","year":"1980","journal-title":"Endocrinology"},{"key":"10.1016\/j.sxmr.2017.02.004_bib23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1210\/endo-114-5-1537","article-title":"On the in\u00a0vitro and in\u00a0vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone","volume":"114","author":"Bowers","year":"1984","journal-title":"Endocrinology"},{"key":"10.1016\/j.sxmr.2017.02.004_bib24","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s000180050257","article-title":"Growth hormone-releasing peptide (GHRP)","volume":"54","author":"Bowers","year":"1998","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.sxmr.2017.02.004_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-381272-8.00001-5","article-title":"History to the discovery of ghrelin","volume":"514","author":"Bowers","year":"2012","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib26","first-page":"3279","article-title":"Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor","volume":"86","author":"Gondo","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1210\/er.2004-0019","article-title":"Development of growth hormone secretagogues","volume":"26","author":"Smith","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.sxmr.2017.02.004_bib28","first-page":"292","article-title":"The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration","volume":"74","author":"Bowers","year":"1992","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1530\/eje.0.1330425","article-title":"Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature","volume":"133","author":"Bellone","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0196-9781(97)00016-8","article-title":"Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH","volume":"18","author":"Arvat","year":"1997","journal-title":"Peptides"},{"key":"10.1016\/j.sxmr.2017.02.004_bib31","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1210\/jc.2003-031799","volume":"89","author":"Bowers","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1507\/endocrj1954.38.15","article-title":"Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men","volume":"38","author":"Hayashi","year":"1991","journal-title":"Endocrinol Jpn"},{"key":"10.1016\/j.sxmr.2017.02.004_bib33","first-page":"1641","article-title":"Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men","volume":"77","author":"Jaffe","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1530\/eje.0.1320712","article-title":"Growth hormone (GH) responses to the combined administration of GH-releasing hormone plus GH-releasing peptide 6 in adults with GH deficiency","volume":"132","author":"Leal-Cerro","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib35","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/0026-0495(95)90016-0","article-title":"Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature","volume":"44","author":"Tuilpakov","year":"1995","journal-title":"Metabolism"},{"key":"10.1016\/j.sxmr.2017.02.004_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1530\/eje.0.1390395","article-title":"A\u00a0five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men","volume":"139","author":"Nijland","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib37","first-page":"943","article-title":"Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects","volume":"79","author":"Aloi","year":"1994","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib38","first-page":"1393","article-title":"Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6","volume":"77","author":"Gertz","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2265.1995.tb02929.x","article-title":"Intranasal administration of the GHRP hexarelin accelerates growth in short children","volume":"43","author":"Laron","year":"1995","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib40","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1515\/JPEM.2003.16.7.981","article-title":"Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children","volume":"16","author":"Mericq","year":"2003","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib41","first-page":"2355","article-title":"Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children","volume":"83","author":"Mericq","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1677\/joe.0.1550079","article-title":"Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature","volume":"155","author":"Pihoker","year":"1997","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1067\/mcp.2001.116514","article-title":"Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children","volume":"70","author":"Codner","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.sxmr.2017.02.004_bib44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/jc.2004-1719","article-title":"Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men","volume":"90","author":"Laferrere","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib45","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/oby.2006.121","article-title":"Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake","volume":"14","author":"Laferrere","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.sxmr.2017.02.004_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jcsm.12028","article-title":"One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient","volume":"6","author":"Haruta","year":"2015","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.sxmr.2017.02.004_bib47","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1046\/j.1365-2265.2002.01255.x","article-title":"The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone","volume":"56","author":"Van den Berghe","year":"2002","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib48","first-page":"320","article-title":"MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism","volume":"83","author":"Murphy","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib49","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1359\/jbmr.1999.14.7.1182","article-title":"Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group","volume":"14","author":"Murphy","year":"1999","journal-title":"J\u00a0Bone Min Res"},{"key":"10.1016\/j.sxmr.2017.02.004_bib50","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1532-5415.2004.52156.x","article-title":"The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture","volume":"52","author":"Bach","year":"2004","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.sxmr.2017.02.004_bib51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.archger.2010.10.004","article-title":"MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study","volume":"53","author":"Adunsky","year":"2011","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.sxmr.2017.02.004_bib52","first-page":"819","article-title":"Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity","volume":"76","author":"Cordido","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib53","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0026-0495(95)90187-6","article-title":"Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects","volume":"44","author":"Cordido","year":"1995","journal-title":"Metabolism"},{"key":"10.1016\/j.sxmr.2017.02.004_bib54","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJM198411293112203","article-title":"Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction","volume":"311","author":"Williams","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sxmr.2017.02.004_bib55","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0026-0495(99)90115-4","article-title":"Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non\u2013insulin-dependent diabetes mellitus","volume":"48","author":"Micic","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.sxmr.2017.02.004_bib56","first-page":"362","article-title":"Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure","volume":"83","author":"Svensson","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib57","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12020-011-9560-4","article-title":"Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study","volume":"41","author":"Sode-Carlsen","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.sxmr.2017.02.004_bib58","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-149-9-200811040-00003","article-title":"Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial","volume":"149","author":"Nass","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sxmr.2017.02.004_bib59","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1159\/000126883","article-title":"Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man","volume":"61","author":"Frieboes","year":"1995","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.sxmr.2017.02.004_bib60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2826.1999.00364.x","article-title":"Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration","volume":"11","author":"Frieboes","year":"1999","journal-title":"J\u00a0Neuroendocrinol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib61","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0306-4530(03)00152-5","article-title":"Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers","volume":"29","author":"Frieboes","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.sxmr.2017.02.004_bib62","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000127249","article-title":"Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man","volume":"66","author":"Copinschi","year":"1997","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.sxmr.2017.02.004_bib63","first-page":"4249","article-title":"Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects","volume":"81","author":"Chapman","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib64","first-page":"1116","article-title":"Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women","volume":"86","author":"Murphy","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2017.02.004_bib65","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/01.wnl.0000335163.88054.e7","article-title":"Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial","volume":"71","author":"Sevigny","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.sxmr.2017.02.004_bib66","first-page":"1","article-title":"Ghrelin receptor ligands reaching clinical trials: from peptides to peptidomimetics; from agonists to antagonists","volume":"48","author":"Vodnik","year":"2016","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.sxmr.2017.02.004_bib67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/dta.120","article-title":"Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement","volume":"2","author":"Thomas","year":"2010","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.sxmr.2017.02.004_bib68","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF00191904","article-title":"Growth hormone-releasing activity of hexarelin in humans","volume":"46","author":"Imbimbo","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.sxmr.2017.02.004_bib69","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.92.15.7001","article-title":"Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue","volume":"92","author":"Patchett","year":"1995","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205005211730032X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205005211730032X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T13:52:50Z","timestamp":1719150770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205005211730032X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S205005211730032X"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2017.02.004","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Safety and Efficacy of Growth Hormone Secretagogues","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2017.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}